Compare TVRD & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TVRD | KYNB |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1M | 31.9M |
| IPO Year | N/A | N/A |
| Metric | TVRD | KYNB |
|---|---|---|
| Price | $3.87 | $6.95 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $51.67 | N/A |
| AVG Volume (30 Days) | ★ 37.0K | 33.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.50 | $6.67 |
| 52 Week High | $43.65 | $9.58 |
| Indicator | TVRD | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 41.05 |
| Support Level | $3.81 | $6.67 |
| Resistance Level | $4.45 | $8.89 |
| Average True Range (ATR) | 0.21 | 0.39 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 38.12 | 21.53 |
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.